{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:42:39Z","timestamp":1792899759265,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C33589\/A28284"],"award-info":[{"award-number":["C33589\/A28284"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C7224\/A28724"],"award-info":[{"award-number":["C7224\/A28724"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000650","name":"Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000650","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000771","name":"Prostate Cancer UK","doi-asserted-by":"publisher","award":["RIA 15-ST2-006"],"award-info":[{"award-number":["RIA 15-ST2-006"]}],"id":[{"id":"10.13039\/501100000771","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.clon.2024.06.047","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T23:10:42Z","timestamp":1718752242000},"page":"585-592","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Stereotactic Body Radiotherapy for Oligoprogression in Castration-Resistant Prostate Cancer: Early Toxicity Analysis of the TRAP Trial"],"prefix":"10.1016","volume":"36","author":[{"given":"P.H.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Dreibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3550-6178","authenticated-orcid":false,"given":"J.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pathmanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tirona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Guevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.-E.","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Frew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Palaniappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5781-2067","authenticated-orcid":false,"given":"I.","family":"Syndikus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Attard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6656-3699","authenticated-orcid":false,"given":"N.","family":"Tunariu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"Tree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2024.06.047_bib1","series-title":"Cancer statistics report for the UK","year":"2023"},{"issue":"21","key":"10.1016\/j.clon.2024.06.047_bib2","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and Increased Survival in Metastatic Prostate Cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.clon.2024.06.047_bib3","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone Acetate plus Prednisone in Patients with Newly Diagnosed High-Risk Metastatic Castration-Sensitive Prostate Cancer (LATITUDE): Final Overall Survival Analysis of a Randomised, Double-Blind, Phase 3 Trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"The Lancet Oncology"},{"issue":"5","key":"10.1016\/j.clon.2024.06.047_bib4","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in Metastatic Prostate Cancer before Chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.clon.2024.06.047_bib5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer","volume":"381","author":"Davis","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.clon.2024.06.047_bib6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer","volume":"381","author":"Chi","year":"2019","journal-title":"The New England Journal of Medicine"},{"issue":"12","key":"10.1016\/j.clon.2024.06.047_bib7","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer","volume":"386","author":"Smith","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"15","key":"10.1016\/j.clon.2024.06.047_bib8","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.clon.2024.06.047_bib9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer","volume":"369","author":"Parker","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1016\/j.clon.2024.06.047_bib10","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.clon.2019.05.015","article-title":"The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively?","volume":"31","author":"Patel","year":"2019","journal-title":"Clinical Oncology (Royal College of Radiologists (Great Britain))"},{"issue":"12","key":"10.1016\/j.clon.2024.06.047_bib11","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.clon.2024.06.047_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.eururo.2015.07.004","article-title":"Progression-Free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-Naive Recurrence: A Multi-Institutional Analysis","volume":"69","author":"Ost","year":"2016","journal-title":"European Urology"},{"key":"10.1016\/j.clon.2024.06.047_bib13","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.clon.2015.03.006","article-title":"Initial UK Experience of Stereotactic Body Radiotherapy for Extracranial Oligometastases: Can We Change the Therapeutic Paradigm?","volume":"27","author":"Aitken","year":"2015","journal-title":"Clinical Oncology"},{"issue":"28","key":"10.1016\/j.clon.2024.06.047_bib14","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1200\/JCO.2016.72.1068","article-title":"Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial\u2014FIRSTANA","volume":"35","author":"Oudard","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clon.2024.06.047_bib15","doi-asserted-by":"crossref","unstructured":"Saad F, Molina A, Li J, Kheoh T, S. H. Exploratory Analysis of the Safety Profile of Abiraterone Acetate (AA) in Patients Receiving Concomitant Radiation Therapy in Patients With Metastastic Castration-Resistant Prostate Cancer., Journal of Urology, Vol. 187 (4S), No. e278.","DOI":"10.1016\/j.juro.2012.02.764"},{"issue":"7","key":"10.1016\/j.clon.2024.06.047_bib16","first-page":"3717","article-title":"Combining Abiraterone and Radiotherapy in Prostate Cancer Patients Who Progressed During Abiraterone Therapy","volume":"37","author":"Detti","year":"2017","journal-title":"Anticancer Research"},{"issue":"1","key":"10.1016\/j.clon.2024.06.047_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-020-06853-x","article-title":"Metastasis-Directed Therapy in Castration-Refractory Prostate Cancer (MEDCARE): A Non-Randomized Phase 2 Trial","volume":"20","author":"Berghen","year":"2020","journal-title":"BMC Cancer"},{"issue":"36","key":"10.1016\/j.clon.2024.06.047_bib18","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1200\/JCO.23.00985","article-title":"Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO)","volume":"41","author":"Francolini","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clon.2024.06.047_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.695136","article-title":"Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer","volume":"11","author":"Massaro","year":"2021","journal-title":"Frontiers in Oncology"},{"issue":"3","key":"10.1016\/j.clon.2024.06.047_bib20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10585-022-10158-7","article-title":"Oligoprogressive Castration-Resistant Prostate Cancer Treated with Metastases-Directed Stereotactic Body Radiation Therapy: Predictive Factors for\u00a0Patients\u2019 Selection","volume":"39","author":"Franzese","year":"2022","journal-title":"Clinical & Experimental Metastasis"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655524002607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655524002607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T06:37:44Z","timestamp":1730097464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655524002607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0936655524002607"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2024.06.047","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic Body Radiotherapy for Oligoprogression in Castration-Resistant Prostate Cancer: Early Toxicity Analysis of the TRAP Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2024.06.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2024 Published by Elsevier Ltd on behalf of The Royal College of Radiologists. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}